# FLUBLOK TRIVALENT NORTHERN HEMISPHERE

NDC: 49281-726
Generic name: INFLUENZA A VIRUS A/Missouri/11/2025 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/Darwin/1415/2025 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/Pennsylvania/14/2025 RECOMBINANT HEMAGGLUTININ ANTIGEN
Labeler / Manufacturer: Sanofi Vaccines US Inc.
Product type: VACCINE
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: INTRAMUSCULAR
Marketing started: 20260702
Marketing ended: 20270630
FDA application: BLA125285

## Active ingredients

- INFLUENZA A VIRUS A/MISSOURI/11/2025 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN: 45 ug/.5mL
- INFLUENZA A VIRUS A/DARWIN/1415/2025 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN: 45 ug/.5mL
- INFLUENZA B VIRUS B/PENNSYLVANIA/14/2025 RECOMBINANT HEMAGGLUTININ ANTIGEN: 45 ug/.5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"49281-726"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=49281-726